Chronic Heart Failure, Hyperuricemia
Conditions
Brief summary
The purpose of this study is to discover whether the inhibition of the xanthine oxidase with allopurinol leads to a reduction of the production of oxygen free radicals in patients with CHF and thereby improves characteristics of oxydative metabolism, peripheral blood flow, immune function and functional status.
Interventions
DRUGAllopurinol
DRUGPlacebo
Sponsors
National Heart and Lung Institute
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient is a male and at least 21 years of age. * The patient has clinical evidence of heart failure: a) reduced ejection fraction (≤40%) or cardiomegaly on CXR or left ventricular impairment on echocardiography (LVEDD ≥60mm), b) stable clinical condition and medication for at least 1 month prior to the study. * No history of unstable angina, myocardial infarction or stroke within 3 months prior to the study. * The patient is receiving full conventional medical therapy for heart failure (ACE inhibitor or angiotensin II blocker, diuretics etc.). * The patient is willing and capable of complying with the requirements of this protocol. * The patient has provided written informed consent .
Exclusion criteria
* The patient has any life-threatening disease, other than heart failure (including patients with known, or suspected, myocarditis or with automatic implantable cardioverter/defibrillators). * The patient has an active malignancy of any type, or history of a malignancy (Patients who have a history of basal cell carcinoma that has been surgically removed are acceptable). Patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years prior to study enrolment are also acceptable. * The patient has had a heart transplant. * The patient has severe renal disease (S-Creatinine \>300 μmol/l), severe liver disease (ASAT or ALAT \> 3 times of upper limit of normal range), rheumatoid arthritis, or complains of gout. * The patients has received allopurinol therapy previously or if he is known to suffer from gout (acutely or chronically). * The patient has an exercise capacity of \> 20 ml/kg/min (treadmill, Bruce protocol) or is in functional NYHA class I.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| postischemic peak peripheral blood flow | — |
Countries
United Kingdom
Outcome results
None listed